Batimastat BiodivYsio stent: BII and BBG started BRILLIANT II, a double-blind, 400-patient pivotal European trial of the Batimastat BiodivYsio stent. The study

Biocompatibles International plc (LSE:BII), Farnham, U.K.
British Biotech plc

Read the full 108 word article

How to gain access

Continue reading with a
two-week free trial.